Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
To identify the path to innovation, in harmony with life
Life is constantly adapting to new conditions. It innovates to keep going. We put our intelligence at your service to guide you towards success. Oncodesign’s culture is based on sharing, mutual assistance, community, sociability and, more generally, solidarity.
Creation by its CEO and founder Philippe Genne, in Dijon, as a pharmacology services company to select the best oncology drug candidates.
Foundation by Oncodesign of a regional center of excellence in pharmaco-imaging to monitor the effect of therapies and identify translational efficacy biomarkers for precision medicine. Pharmimage brings together hospitals, biotechnology and pharmaceutical companies in Dijon, France.